CVRx, Inc. Common Stock CVRX

CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.

• GlobeNewswire Inc. 25 ago

  CVRx Responds to Letter from Pointillist Family Office

  CVRx's Board of Directors responded to a public letter from Pointillist Family Office shareholder Jorey Chernett, acknowledging that the company's valuation does not fully capture its business potential. The Board affirmed confidence in Barostim's differentiated position as the only FDA-approved neuromodulation therapy for heart failure and committed to pursuing strategies to drive growth while managing expenses. The Board remains open to shareholder engagement.

  

• GlobeNewswire Inc. 10 ago

  CVRX INVESTIGATION: CVRx, Inc. Investigated for Securities Fraud by Block & Leviton; Investors Should Contact the Firm to Possibly Recover Losses

  Block & Leviton is investigating CVRx, Inc., Papa John's International, and HubSpot for potential securities fraud. CVRx cut its revenue guidance citing sales force challenges and reimbursement issues, while HubSpot experienced a 25% share price decline. Investors who have suffered losses are encouraged to contact the firm.

  

• GlobeNewswire Inc. 7 ago

  CVRx, Inc. (CVRX) Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel Following Revenue Guidance Cut and Sales-Execution Disclosures

  Johnson Fistel is investigating CVRx, Inc. for potential securities law violations following the company's August 6, 2026 revenue guidance cut from $63-67 million to $58-60 million. The downward revision was attributed to sales force execution challenges, high employee turnover, slower productivity ramps, and reimbursement issues with a major Medicare Advantage payer. CVRx also disclosed receiving a Department of Justice civil investigative demand regarding sales and marketing practices.